Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli(Institute of Oncology Research), Francesco Bertoni(Institute of Oncology Research)
Cited by 41
Related Papers
Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma
|British Journal of Haematology|2017|40